When a disease is as relentless as amyotrophic lateral sclerosis (ALS; aka Lou Gehrig’s disease; aka motor neuron disease), any promising research result is welcome news.
A study just published in Science Advances shows that two drugs already FDA-approved for other diseases, when teamed, halt neuron death and bolster muscle contraction in an “organ-on-a-chip” model of ALS. When the drugs meet in a device that places tiny balls of motor neurons from a patient next to strips of healthy skeletal muscle, the set-up not only recapitulates the disease, but shows the synergy of the drugs. They are rapamycin (Sirolimus) and bosutinib (Bosulif).
To continue reading go to DNA Science, my blog at Public Library of Science, where this post first appeared.
A study just published in Science Advances shows that two drugs already FDA-approved for other diseases, when teamed, halt neuron death and bolster muscle contraction in an “organ-on-a-chip” model of ALS. When the drugs meet in a device that places tiny balls of motor neurons from a patient next to strips of healthy skeletal muscle, the set-up not only recapitulates the disease, but shows the synergy of the drugs. They are rapamycin (Sirolimus) and bosutinib (Bosulif).
To continue reading go to DNA Science, my blog at Public Library of Science, where this post first appeared.